Basilea Stresses Derazantinib's FGFR Kinase Differentiation
Tumor Checkpoint Controller Also In Early Clinical Studies
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
You may also be interested in...
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.
Results from two studies at ESMO point to a targeted future for cholangiocarinoma with Agios and Incyte both planning year-end FDA filings in different patient subsets.
Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.